ERA PerMed 2020 - Multidisciplinary research projects on personalised medicine - pre-/clinical research, big data and ICT, implementation and user's perspective

Precision drugs Against Resistance In Subpopulations – PARIS

Submission summary

In high-grade serous ovarian cancer (HGSOC) there is an urgent medical need for effective treatment options for the patients with a limited response to both standard chemotherapy and emerging PARP inhibitors. Apart from the mutations in DNA repair pathways, targetable point mutations in tumour suppressors are uncommon in HGSOC tumours. Instead, patients present unique and highly variable combinations of copy number aberrations, structural variations and additional subclonal changes, significantly complicating classification and targeting of intratumoral chemoresistance-associated heterogeneity across patients. Thus, innovative personalised approaches are required to help these patients.

To overcome treatment resistance in HGSOC, we propose to implement a novel concept: to unbiasedly detect the distinct tumour subpopulations that confer resistance to current therapies, and then to predict and test which drugs they respond to. We propose to implement this concept by combining [i] a novel, unbiased, and robust algorithm to reliably identify the resistant tumour cell subpopulations from single cell transcriptomic data of HGSOC tumours and matched organoids, [ii] drug response prediction and screening in organoid cultures, using single cell readouts, and [iii] validation of the resulting personalised drug predictions in independent samples, in both organoid cultures and in vivo patient-derived xenografts, co-treated with chemotherapy.

Our novel approach enables the design of effective personalised treatments of HGSOC to complement chemotherapy by targeting the specific chemoresistance mechanisms active in each patient’s tumour cell subpopulations. The resulting tools and biomarkers can be used for screening and prioritisation; first, in early-phase patient-centric studies, and then in larger trials. The overall approach can be extended to other diseases where subpopulations provide treatment resistance, towards a paradigm shift in personalised oncology.

Project coordination

Benno SCHWIKOWSKI (Institut Pasteur)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

IP Institut Pasteur

Help of the ANR 1,198,968 euros
Beginning and duration of the scientific project: March 2021 - 36 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter